Registry update — unassessed
Senescence, Frailty, and Mesenchymal Stem Cell Functionality in Chronic Kidney Disease: Effect of Senolytic Agents
Trial registry update: ENROLLING_BY_INVITATION. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: May 19, 2026 · Discovered: Sep 15, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The study abstract does not report actual findings, sample size, or effect sizes, making it impossible to determine whether senolytic agents had any benefit on frailty or other outcomes.
- Without reported results, this cannot demonstrate whether senolytic treatment is effective, ineffective, or harmful in the CKD population.
- The design as a trial establishes it could in principle test causation, but the absence of outcome data means no causal claim can be evaluated.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Patients with chronic kidney disease (CKD)
- Primary outcome
- Senescence burden
- Effect size
- —
- Significance
- Not reported
- Journal
- Mayo Clinic
- Published
- May 19, 2026
Sources
Primary source
- Mayo Clinic ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
The study goal is to assess the effect of senescent cell clearance on senescence burden, physical ability or frailty, and adipose tissue-derived mesenchymal stem cell (MSC) functionality in patients with chronic kidney disease (CKD).
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.